INO - イノバロン・ホ―ルドング (Inovio Pharmaceuticals Inc.) イノバロン・ホ―ルドング

 INOのチャート


 INOの企業情報

symbol INO
会社名 Inovalon Holdings Inc (イノバロン・ホ―ルドング)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 バイオテクノロジ―_メディカルリサ―チ   IT・通信(IT_Communications)
概要 事業概要 アイノビオ・ファーマスーティカル(Inovio Pharmaceuticals Inc.)は癌と感染症の治療・予防に従事するデオキシリボ核酸(DNA)免疫療法とワクチンの開発を行う臨床段階の製薬会社である。同社のDNAベースの免疫療法はエレクトロポレーション送達デバイスと組み合わせて、標的疾患と戦う体内にある免疫応答、特にT細胞を生成する。同社はヒトパピローマウイルス(HPV)に起因する前癌・癌、インフルエンザ、前立腺癌、乳癌・肺癌・膵臓癌、C型肝炎ウイルス(HCV)、B型肝炎ウイルス(HBV)、ヒト免疫不全ウイルス(HIV)、エボラ、中東呼吸器症候群(MERS)及びジーファウイルスに対するSynCon免疫療法の臨床計画を完成する。同社は免疫療法プラットフォーム及びCELLECTRAエレクトロポレーション送達技術により、インビボ免疫応答を生じる前臨床・臨床段階製品のパイプラインを所有する。   イノバロン・ホ―ルドングは、米国の持株会社。医療にクラウドベ―スのデ―タ分析とデ―タ駆動介入プラットフォ―ムを組み合せた技術展開する。分析では、ケア、品質、デ―タの整合性、および財務実績のギャップを特定する。この差別組み合わせは、計画、病院、医師、患者、製薬会社や研究者のためのプラットフォ―ムを提供する。   Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
本社所在地 4321 Collington Road Bowie MD 20716 USA
代表者氏名 Jong Joseph Kim ジョン・ジョセフ・キム
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 858-410-3134
設立年月日 41883
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 2480人
url www.inovalon.com
nasdaq_url https://www.nasdaq.com/symbol/ino
adr_tso
EBITDA EBITDA(百万ドル) -86.82719
終値(lastsale) 5.37
時価総額(marketcap) 491338003.95
時価総額 時価総額(百万ドル) 497.74280
売上高 売上高(百万ドル) 37.41017
企業価値(EV) 企業価値(EV)(百万ドル) 402.14780
当期純利益 当期純利益(百万ドル) -94.63071
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Inovio Pharmaceuticals Inc revenues decreased 16% to $26M. Net loss increased 20% to $39M. Revenues reflect Grants and miscellaneous revenue decrease of 99% to $95K Grants and miscellaneous revenue from af decrease from $1.7M to $0K Revenue under collaborative research and decrease of 49% to $208K. Higher net loss reflects General and administrative - Balancing v increase of 50% to $14.6M (expense).

 INOのテクニカル分析


 INOのニュース

   Inovio Pharmaceuticals-Aktie: Auf den zweiten Blick nicht überzeugend - deshalb sollten Anleger Abstand halten  2020/05/29 14:00:00 BORSE ONLINE
Als die Covid-19-Pandemie in Europa und dann auch in den USA so richtig Fahrt aufnahm, stellte BÖRSE ONLINE mögliche Entwickler von Impfstoffen vor. Spektakuläre Kurssteigerungen verzeichnete etwa die Aktie von Inovio Pharmaceuticals (WKN: A11 5GK), die in Ausgabe 11/2020 kurz besprochen wurde.
   Inovio Can Climb Higher, Says Top Analyst  2020/05/22 13:42:12 Yahoo Finance
The race to develop a vaccine against COVID-19 is charging full speed ahead. Yesterday, Inovio Pharmaceuticals (INO) released promising preclinical data for the biotech’s COVID-19 DNA vaccine candidate, INO-4800. Investors have high hopes for the vaccine maker and have sent the stock soaring by over
   Inovio Analysts Bullish On Prospects For Coronavirus Vaccine, Biotech's Pipeline  2020/05/21 18:52:03 Benzinga
A day after short seller Citron Research slammed Inovio Pharmaceuticals Inc (NASDAQ: INO ), sell-side analysts lined up behind the company. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter . The Inovio Analysts Benchmark analyst Aydin Huseynov initiated shares of Inovio with a Buy rating and $28 price target. H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $17 price target. Inovio Shares To Benefit From Likelihood of Financing For COVID Vaccine, Benchmark Says Inovio's SARS-CoV-2 vaccine candidate INO-4800 has a meaningful chance of progressing to Phase 2/3 in the July-August timeframe and securing the necessary financing from the government or nonprofits, Benchmark analyst Huseynov said in a note. Noting that Inovio has a pipeline of vaccine candidates for various infectious diseases such as HIV, Ebola, MERS and Zika, the analyst said … Full story available on Benzinga.
   Citron Questions Inovio's 'Robust' Preclinical Coronavirus Vaccine Announcement, Sees 90% Downside Ahead  2020/05/20 19:02:04 Benzinga
Inovio Pharmaceuticals Inc (NASDAQ: INO ) said Wednesday that positive preclinical data for its DNA vaccine for the SARS-CoV-2 has been published in a peer-reviewed journal, sending its shares higher. Inovio's Preclinical Data News Stale? Following the announcement, short seller Citron Research came down heavily on the company, stating in its report that the announcement is not a fresh one and calling for the SEC to halt trading in the stock. "We immediately began preclinical testing and small-scale manufacture and have already shared robust preclinical data with our public and private partners," Inovio's CEO Dr. Joseph Kim … Full story available on Benzinga.com
   Inovio diz que vacina da Covid-19 produz anticorpos em ratos  2020/05/20 15:24:00 Extra
Por Deena Beasley(Reuters) - A empresa norte-americana de imunoterapia Inovio Pharmaceuticals disse nesta quarta-feira que sua vacina experimental para evitar infecções de coronavírus mostrou produção de anticorpos… Leia mais
   Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Inovio Pharmaceuticals, Inc. - INO  2020/03/18 23:53:00 Benzinga Feeds
RADNOR, Pa. , March 18, 2020 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) ("Inovio") on behalf of those who purchased or otherwise acquired Inovio common stock between February 14, 2020 and March 9, 2020 , inclusive (the "Class Period"). Investors who purchased or otherwise acquired Inovio common stock during the Class Period may, no later than May 12, 2020 , seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please click https://www.ktmc.com/inovio-pharmaceuticals-securities-class-action?utm_source=PR&utm_medium=link&utm_campaign=inovio . According to the complaint, Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from infectious diseases. The worldwide outbreak of the novel coronavirus, COVID-19, has become a global "pandemic" due to its extraordinary speed and scale of transmission.
   INVESTOR ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Filed Against Inovio Pharmaceuticals, Inc. (INO) and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2020/03/18 23:30:00 Business Wire
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) on behalf of investors who purchased shares of the Company’s stock between February 14, 2020 and March 9, 2020, inclusive (the “Class Period”). Inovio investors who suffered investment losses in excess of $100,000 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585 or (88
   Investor Suit Alleges Pharma Company Made False Claim of COVID-19 Vaccine  2020/03/18 05:00:48 Insurance Journal
Pennsylvania-based Inovio Pharmaceuticals is the target of a planned class action lawsuit alleging it falsely claimed it has developed a vaccine for COVID-19 that would go into testing as soon as next month. But the pharmaceutical firm has said the …
   INVESTOR ALERT: Kirby McInerney LLP Announces That a Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc.  2020/03/17 21:22:00 Business Wire
NEW YORK--(BUSINESS WIRE)---- $INO #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of those who acquired Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) securities during the period from February 14, 2020 through March 9, 2020. Investors have until May 12, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit. The lawsuit alleges that the Co
   INO SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Alerts Inovio Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2020/03/17 14:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the Company”) (NASDAQ: INO) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Inovio securities between February 14, 2020 and March 9, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/ino.
   U.S.-based Inovio Pharmaceuticals says it has a coronavirus vaccine  2020/02/14 16:42:12 Yahoo Finance
A U.S. biotech company says it has created a coronavirus vaccine. Pennsylvania-based Inovio Pharmaceuticals' San Diego lab made the discovery reportedly just hours after getting access to the virus' genetic sequence last month. Inovio Pharmaceuticals CEO Dr. J Joseph Kim joins Yahoo Finance's On the Move to discuss.
   A Vaccine for Coronavirus? These 3 Healthcare Stocks Are Working on It  2020/02/12 14:30:07 Nasdaq
Fear and uncertainty have gripped the global population as the number of confirmed coronavirus cases grows daily. What started in Wuhan, the capital of China’s Hubei province, has now spread to 43,101 people in 25 different countries, according to the World Health Organization (WHO), killing over 1,000. While 75% of the infections have occurred in the Hubei province, a worldwide effort to contain the virus, now deemed as COVID-19 by WHO, is underway. These efforts include a two-day forum to create a “global research agenda” as well as quarantining individuals returning from the virus’ epicenter for 14 days, with the first 195 U.S. citizens under quarantine being released on February 11. The Centers for Disease Control and Prevention (CDC) has confirmed that 13 people in the U.S. have been infected, with the most recent case in San Diego after a repatriated individual that originally tested negative for the virus developed symptoms. As so much about COVID-19 remains unknown, it has become a race against the clock to find solutions.
   Here's Why Inovio Pharmaceuticals Jumped Higher Today | The Motley Fool  2020/02/10 17:56:00 The Motley Fool
The company is starting a new clinical trial, but that may not be the only thing boosting the biotech's shares.
   Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)  2020/02/10 11:00:00 PR Newswire
/PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New…
   It could take years and cost $1 billion to make a vaccine for the Wuhan coronavirus. But top scientists told us the work could still help halt future outbreaks.  2020/02/08 13:37:00 Business Insider
Drugmakers are working on vaccines to counter the spreading Wuhan coronavirus . But it will take years to fully test the injections, experts told Business Insider. The research still holds great value for public health, as another coronavirus outbreak is likely to happen in the future. "It will be folly to think that this won't happen again," said Dr. Gregory Poland , director of the Mayo Clinic's Vaccine Research Group. "It absolutely will, and history has shown that to be the case." Previous efforts to make vaccines for similar outbreaks didn't progress beyond early studies focused on safety. It remains to be seen if new nonprofits focused on vaccines can bring development efforts to completion in this case. Visit Business Insider's homepage for more stories . As drugmakers race to come up with vaccines to halt the deadly Wuhan coronavirus outbreak, their efforts are likely to come up against the same challenges that have hindered previous searches. Chief among them: a coronavirus vaccine will most likely take years of development and testing before it can reach a large population, experts told Business Insider.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イノバロン・ホ―ルドング INO Inovio Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)